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A host of cancer types exhibit aberrant histone modifications. Recently, distinct and recurrent mutations in a
specific histone variant, histone H3.3, have been implicated in a high proportion of malignant pediatric brain
cancers. The presence ofmutant H3.3 histone disrupts epigenetic posttranslational modifications near genes
involved in cancer processes and in brain function. Here, we review possible mechanisms by which mutant
H3.3 histones may act to promote tumorigenesis. Furthermore, we discuss how perturbations in normal H3.3
chromatin-related and epigenetic functions maymore broadly contribute to the formation of human cancers.Histones are linked to the genesis of a multitude of cancers pri-
marily through alterations in their posttranslational modification
(PTM) and the epigenetic machinery controlling these modifica-
tions. Recurrent mutations in histone-modifying enzymes and
chromatin remodelers are apparent in various cancer types
(Dawson and Kouzarides, 2012), and a number of studies have
together provided growing insight into the interplay among
histone-modifying enzymes, specific histone PTMs, and tumor-
igenesis (Suva` et al., 2013).
Emerging lines of investigation are focused on cancer-related
mutations in histones themselves as recent studies estimate that
30%–40% of sequenced glioblastoma multiforme (GBM) tumors
contain some disruption in epigenetic regulatory machinery, with
roughly 11% of all samples bearing specific and recurring his-
tone mutations (Sturm et al., 2012). When stratified by patient
age, these estimates become much more striking. Approxi-
mately 70%–80% of pediatric gliomas are characterized by pre-
cisely the same histone mutations manifested in the variant
member of the histone H3 family, H3.3 (Attieh et al., 2013; Bjerke
et al., 2013; Chan et al., 2013; Fontebasso et al., 2013a, 2013b;
Gessi et al., 2013; Je et al., 2013a, 2013b; Jones et al., 2013;
Khuong-Quang et al., 2012; Lewis et al., 2013; Schwartzentruber
et al., 2012; Sturm et al., 2012; Venneti et al., 2013;Wiestler et al.,
2013; Wu et al., 2012; Zhang et al., 2013). Together, these
studies strongly implicate three separate, specific amino acid
substitution mutations in H3.3 in the pathogenesis of several
forms of human pediatric gliomas, including GBM and diffuse
intrinsic pontine glioma (DIPG).Unique Qualities of Histone Variant H3.3
The human histone H3 family consists of a number of related pro-
teins: H3.1 and H3.2 (commonly referred to as ‘‘canonical’’ H3),
histone variant H3.3, the centromere-specific variant CENP-A/
CenH3, the testes-specific H3t (Szenker et al., 2011), and the
testes-specific H3.5 (Schenk et al., 2011). In eukaryotes, there
are two genes, known as H3f3a and H3f3b in mice and H3F3A
and H3F3B in humans, that produce identical H3.3 proteins
though each contains different mRNA untranslated regions and
regulatory sequences (Akhmanova et al., 1995; Albig et al.,1995;Wells et al., 1987;Witt et al., 1997).While H3.3 can function
much the same as canonical H3 as a core part of the nucleo-
some, H3.3 is also deposited into transcriptionally active regions
to replace displaced nucleosomes throughout the cell cycle (Ah-
mad and Henikoff, 2002; Ray-Gallet et al., 2011; Tagami et al.,
2004), in contrast to its canonical counterparts H3.1 and H3.2,
which are deposited in a replication-dependent manner. H3.3
is found in genomic regions exhibiting ‘‘active’’ or ‘‘poised’’ tran-
scription—domains commonly enriched for lysine 4 trimethyla-
tion of H3 (H3K4me3) or possessing both lysine 27 trimethylation
(H3K27me3) and H3K4me3 (Delbarre et al., 2010)—in addition to
pericentromeric and telomeric regions (Szenker et al., 2011).
H3.3 comprises approximately 25% of the total pool of H3 his-
tones inDrosophilamelanogaster (Sakai et al., 2009) and is found
at comparable levels in Mus musculus (Bush et al., 2013).Insight Gained from H3.3 Pathway Disruption
Two major histone chaperone complexes have been identified
as responsible for H3.3 incorporation: histone regulator A
(HIRA), which incorporates H3.3 into genic, euchromatic regions
in a replication-independent manner (Goldberg et al., 2010; Ta-
gami et al., 2004), and the death-associated protein (DAXX)/
a-thalassemia X-linked mental retardation protein (ATRX) com-
plex, which incorporates H3.3 into pericentromeric and telo-
meric heterochromatin regions (Delbarre et al., 2013; Drane´
et al., 2010; Goldberg et al., 2010) and in response to neuronal
signaling (Michod et al., 2012). Loss of HIRA, the major chap-
erone responsible for H3.3 deposition, causes defects in early
embryogenesis (Roberts et al., 2002; Szenker et al., 2012); loss
of ATRX results in aneuploidy and defects in chromosomal
segregation (Baumann et al., 2010). Both ATRX and DAXX
have been reported as factors mutated in neuroblastoma
(Cheung et al., 2012) and in other cancer types (Heaphy et al.,
2011; Jiao et al., 2011). Thus, the interplay between ATRX/
DAXX and H3.3 histones may represent a critical, yet unex-
plored, axis leading to pediatric gliomas.
Loss-of-function studies for genes encoding H3.3 have also
proven insightful. Individual homozygous disruption of His3.3A
and His3.3B in Drosophila (orthologs of human H3F3A andCancer Cell 24, November 11, 2013 ª2013 Elsevier Inc. 567
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contrast, combined disruption of both genes results in reduced
viability and sterility (Ho¨dl and Basler, 2009; Sakai et al., 2009).
H3.3may be necessary to sustain transcription of genes involved
in differentiation, as knockdown of H3.3 by morpholino in Xeno-
pus laevis leads to defects in late gastrulation developmental
programs (Szenker et al., 2012), and the introduction of a domi-
nant-negative form of H3.3 in zebrafish disrupts neural crest
development (Cox et al., 2012). Loss-of-function studies of
H3.3 in mammals have only disrupted one of the two H3.3-
encoding genes successfully in mice (Bush et al., 2013; Couldrey
et al., 1999; Tang et al., 2013), though disruption of either H3f3a
or H3f3b imparts developmental defects, neonatal lethality, and
reduced fertility.
At the chromatin level, loss of H3.3 in Drosophila results in a
compensatory gap-filling mechanism, whereby HIRA and XNP
(the Drosophila ATRX homolog) are bound to previously H3.3-
associated regions (Schneiderman et al., 2012). In the mouse,
H3.3 acts as a placeholder for CENP-A during cell division (Dun-
leavy et al., 2011), and partial loss-of-function of H3.3 via
knockout of H3f3b causes ectopic CENP-A foci formation
(Bush et al., 2013), with CENP-A acting in a possible compensa-
tory gap-filling mechanism for lost H3.3. Partial loss of H3.3 in
Mus also results in defects in cell cycling as well as chromosomal
and karyotypic abnormalities (Bush et al., 2013). Similarly,
knockdown of H3.3 leads to embryonic developmental arrest,
chromosome missegregation, and chromatin condensation (Lin
et al., 2013). Collectively, these data suggest that H3.3 may be
necessary for proper chromosome segregation. These studies
have also provided insight into the normal function of endoge-
nous H3.3 in the genome and have raised additional possibilities
of what goes awry with H3.3 mutations in cancer.
H3.3 as an Epigenetic Memory and Plasticity Factor
How might H3.3 influence epigenetic states? Studies in
Drosophila found that only specific residues in place of lysine 4
(a K4 arginine replacement, but not K4 alanine) could restore de-
fects in fertility upon H3.3 removal (Ho¨dl and Basler, 2009; Sakai
et al., 2009), suggesting that the incorporation of a specific PTM,
and not just the histone itself, is necessary for proper germ cell
function. In Xenopus, H3.3 overexpression augmented an
embryo’s memory of the transcriptional state of donor nuclei
genes following nuclear transfer to an enucleated egg (Ng and
Gurdon, 2008). H3.3 was heavily incorporated into regions ex-
hibiting this epigenetic memory. When K4 of H3.3 was replaced
with glutamic acid [K4E], incorporation of K4E effectively
silenced regions that were previously transcriptionally active
(Ng and Gurdon, 2008; Yang et al., 2011). The presence of
H3K4me3 marks is strongly associated with active transcription,
and H3.3 protein is enriched for PTMs associated with active
transcription when compared to its canonical H3 counterparts
(Hake et al., 2006; McKittrick et al., 2004), further supporting
the notion that modification of the N-terminal tail of H3.3
(H3.3K4 methylation, for example) and the pattern of H3.3 incor-
poration uniquely affect the transcriptional state of a cell (Ng and
Gurdon, 2008).
InMus, exploration of mutations on the N-terminal tail of H3.3
revealed that incorporation of a lysine 27 to arginine [K27R]
mutant form of H3.3 (and not canonical H3.1) in zygotes altered568 Cancer Cell 24, November 11, 2013 ª2013 Elsevier Inc.embryonic stage-specific development, caused nuclear segre-
gation abnormalities, and decreased H3K27me3 levels by
approximately 65% (Santenard et al., 2010). The same H3.3
mutation was not found in pediatric gliomas (K27R instead of a
lysine 27 to methionine [K27M] substitution), but the data none-
theless demonstrate the adverse consequences from contin-
uous incorporation of K27-mutated H3.3 histone. One such
consequence is a failure to establish or delineate proper hetero-
chromatic regions. Finally, recent studies in Xenopus have
established that H3.3 and HIRA are necessary to reprogram a
nucleus from one transcriptional state to another (Jullien et al.,
2012). Thus, H3.3 appears to play a major role in transcriptional
plasticity.
Reprogramming somatic cells to produce induced pluripotent
stem cells has some parallels to tumorigenesis, particularly in re-
gard to the transcriptional programs activated (Riggs et al., 2013;
Suva` et al., 2013). The transcriptional plasticity function of H3.3
may be needed to activate genes during oncogenic transforma-
tion as it is needed for maintaining transcriptional memory (Ng
and Gurdon, 2008) or for switching transcriptional states (Jullien
et al., 2012). It remains to be seen what role H3.3 may play in
early oncogenic processes.
H3.3 Mutations and Gliomagenesis
All reported H3.3 mutations identified in human tumors have
been in the H3F3A gene leading to single codon changes within
the N-terminal tail of the H3.3 protein, a region enriched in PTMs.
The first studies identified mutations encoding a K27M substitu-
tion in addition to a smaller number of mutations encoding a
glycine 34 to arginine or valine [G34R/V] substitution (Schwart-
zentruber et al., 2012; Wu et al., 2012). Relatively fewer gliomas
exhibited K27M substitutions in HIST1H3B, one gene of several
encoding canonical H3.1 histone; interestingly, H3.1 mutations
appear to be restricted to DIPG and non-brainstem pediatric
GBM in a younger range of patients (median = 4.75 years; Wu
et al., 2012). In tumor samples, H3.3K27M and H3.3G34R/V
mutations are heterozygously expressed, with one allele of
H3F3A being wild-type (Schwartzentruber et al., 2012). K27M
and G34R/V mutations are mutually exclusive in tumors and
showdistinct gene expression profiles andDNAmethylation pat-
terns (Schwartzentruber et al., 2012; Sturm et al., 2012). Mutated
tumors display different patterns of localization within the central
nervous system that correlate to the normal patterns of brain
expression in which the tumors are found. K27M tumors (both
low- and high-grade) are primarily restricted to midline locations
(spinal cord, thalamus, pons, brainstem) and G34R/V tumors to
cerebral hemispheres (Figure 1A; Bjerke et al., 2013; Sturm
et al., 2012). Additionally, both mutations correspond to different
patient age ranges (Figure 1B), with K27Mmutations more prev-
alent in younger patients (range, 5–29 years) and G34R/V muta-
tions occurring in slightly older patients (range, 9–42 years)
(Schwartzentruber et al., 2012; Sturm et al., 2012). These data
together suggest that K27M and G34R/V mutations may arise
from independent cellular precursors and nicheswithin the brain,
and at different developmental time points.
Intriguingly, H3.3 mutations are also found to simultaneously
overlap with other specific mutations within the same tumor
(Figure 1A). Approximately 30% of K27M mutations are associ-
ated with mutations in ATRX/DAXX and 60% with mutations in
Figure 1. Distribution and Characteristics of
H3.3-Mutated Gliomas
G34R/V and K27M mutations of H3F3A display
distinct and independent characteristics from one
another.
(A) Characteristics of H3.3-mutated tumors.
G34R/V mutations (gray, top) in H3F3A localize
primarily to cerebral/cortical hemispheres, specif-
ically in frontal, parietal, occipital, and temporal
lobes. K27M mutations (pink, bottom) in H3F3A
localize primarily to midline locations, including
the spinal cord, thalamus, pons, and brainstem.
G34R/V mutations significantly overlap with
mutations in TP53 and ATRX/DAXX, but are also
found simultaneously at low rates with mutations in
PDGFRA. K27M mutations overlap with mutations
in TP53 and ATRX/DAXX, although not at signifi-
cantly different rates over control groups. In addi-
tion, K27M mutations are found simultaneously at
low rates with mutations in NF-1, PDGFRA, BRAF,
KRAS, and FGFR1. Mutations in H3.3 directly
(K27M) or indirectly (G34R/V) alter posttransla-
tionally modified residues. G34R/V mutations
appear to affect K36me3 levels, possibly through
inhibition of the methyltransferase SETD2, while
K27M mutations attenuate EZH2 methyltransfer-
ase function, decreasing global K27me3 levels.
(B) Age of onset of H3.3-mutated tumors. K27M
mutations are more prevalent in younger patients
(median age, 11 years) while G34R/Vmutations are
more prevalent in older patients (median age,
20 years). The age distribution and tumor charac-
teristics together suggest that H3.3 mutations
arise at different developmental time points as well
as from independent niches and cellular pre-
cursors within the brain. Age distributions for
K27M and G34R/V tumors were obtained from
Sturm et al. (2012).
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also been found at much lower frequency alongside mutations
in NF-1, PDGFRA, BRAF, KRAS, and FGFR1 in gliomas (Jones
et al., 2013; Khuong-Quang et al., 2012; Schwartzentruber
et al., 2012; Zhang et al., 2013). Meanwhile, G34R/V mutations
completely overlap with tumors containing mutations in TP53
and ATRX/DAXX, but have also been found together with
mutations in PDGFRA (Schwartzentruber et al., 2012). Mutations
in IDH1 and IDH2, which are commonly found in adult
GBM, were largely absent from mutant H3.3 tumors (Khuong-
Quang et al., 2012; Schwartzentruber et al., 2012). Tumors
with mutations in H3F3A, TP53, and ATRX/DAXX contain a
higher abundance of copy number alterations (CNAs) (Schwart-
zentruber et al., 2012), although there was not a clear association
between increases in CNAs and H3F3A mutations alone. Given
that H3F3A mutations are found in heterozygous form and
that these gliomas exhibit similar rates of TP53 mutation with
other glioma types, H3.3K27M and H3.3G34R/V may act as
driver mutations with TP53 mutations occurring as a second
hit (Khuong-Quang et al., 2012; Schwartzentruber et al.,
2012), although it is important to note that G34R/V mutations
display much higher association with mutations in ATRX/DAXX
and TP53.Cancer Cell 24, NHow might N-terminal tail mutations on
H3.3 promote gliomagenesis? H3.3 nor-
mally incorporates into regions that areactively transcribed and exhibit nucleosome displacement, and
is the major histone variant synthesized outside of S-phase in a
number of cell types, including differentiated brain cells that
could give rise to glioblastoma (Meshorer, 2007; Pin˜a and
Suau, 1987; Wu et al., 1982). Mutations in H3F3A (H3.3) are ex-
pected to manifest far more than mutations in HIST1H3B (H3.1),
becauseHIST1H3B is only one gene of many encoding H3.1 and
is only expressed at one point in the cell cycle. In addition to
directly modifying residues at, or near, critical epigenetically
regulated sites, mutation of the N-terminal tail could alter recog-
nition of H3.3 by chromatin remodeling enzymes or chaperones,
leading to aberrant mutant H3.3 incorporation. This in turn may
disrupt normal ATRX/DAXX-mediated incorporation of H3.3 in
pericentromeric regions and furthermore negatively affect chro-
mosomal segregation and genome integrity as was observed
when H3.3 levels were reduced experimentally (Bush et al.,
2013; Lin et al., 2013). Alternatively, these mutations could affect
H3.3 turnover kinetics, induce conformational changes that
disrupt normal chromatin architecture, or even disrupt the PTM
of residues near K27 or G34. Strong evidence from the earliest
studies (Schwartzentruber et al., 2012; Wu et al., 2012) and sup-
ported by more recent work (discussed further below) suggests
that H3F3A mutations act in a dominant negative manner andovember 11, 2013 ª2013 Elsevier Inc. 569
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near K27 or G34 of H3.3 that may drive oncogenic processes.
The overlapping association between TP53/H3F3A mutations
in pediatric gliomas or TP53/IDH1 mutations in adult gliomas
(Schwartzentruber et al., 2012; Sturm et al., 2012) suggests
that IDH1 and H3F3A mutations at least in part affect similar
pathways. In this regard, IDH1 mutations may lead to the pro-
duction of an onco-metabolite that inhibits H3 and H3.3 K27
and K36 histone demethylases, potentially affecting the same
residues mutated in H3.3 mutant gliomas (Fontebasso et al.,
2013b; Schwartzentruber et al., 2012). Methylation of H3K27 is
a marker of heterochromatic states typically associated with
transcriptional repression, mediated through the Polycomb
repressive complex (PRC; Ringrose et al., 2004). Although G34
cannot be directly posttranslationally modified, it is just two
amino acid residues away from K36, a critical residue that is a
marker of euchromatic states when methylated (Wagner and
Carpenter, 2012).
The Polycomb Connection
Although introduction of the H3.3K27M mutation into p53-null,
nestin-expressing progenitors in the neonatal mouse brainstem
was unable to generate gliomas, the expression of H3.1/
H3.3K27M did lead to precancerous changes in the form of
ectopic, proliferative cell clusters in 72% of mice (Lewis et al.,
2013). H3.3K27M expression in cultured DIPG coincided with
reduced global levels of K27me3 and increased acetylation of
K27 (K27Ac; Chan et al., 2013; Lewis et al., 2013), a mark that
is mutually exclusive to K27me3 and is associated with active
transcription. K27M nucleosomes not only inhibit K27me3 on
the same and nearby nucleosomes, but also result in modest in-
creases in K27Ac on H3/H3.3 (Lewis et al., 2013). Similar results
were found in mouse embryonic fibroblast cells, human astro-
cytes, and 293T cells in which H3.3K27M was introduced
(Chan et al., 2013; Lewis et al., 2013). K27Mpeptide allosterically
inhibited methyltransferase activity of the Polycomb repressive
complex group 2 (PRC2) member, enhancer of zeste homolog
2 (EZH2), on wild-type nucleosomes in a dose dependent
manner (Lewis et al., 2013), and H3.3K27M histone protein
strongly immunoprecipitates with EZH2 (Chan et al., 2013), sug-
gesting an interaction between K27M and the EZH2 active site.
However, K27M peptides do not seem to interact with the
PRC2 group member EED, which specifically recognizes
H3K27me3 residues (Lewis et al., 2013; Margueron et al.,
2009), suggesting that K27M may mimic K27me1/me2 residues
in vivo. Finally, in a cohort of brain tumors, 6/20 GBM tumors dis-
playing lowered or absent levels of H3K27me3 also bore H3F3A
K27M mutations (Venneti et al., 2013). Therefore, the K27M
mutation likely acts to alter global H3K27me3 levels through in-
hibition of PRC2 in regions where mutant histones are deposited
(Figure 1A), although other components of PRC2 (i.e., SUZ12,
EZH1) may also be involved (Shen et al., 2008; Xu et al., 2010).
Deregulated expression of PRC members and their target
genes is implicated in a variety of cancer types (Bracken and
Helin, 2009; Hock, 2012; Sparmann and van Lohuizen, 2006).
The methyltransferase activity of EZH2 may be an important
contributor to GBM formation, because EZH2 is expressed at
higher levels in GBM tumors when compared to other tumor
types. However, a significant difference in EZH2 levels was not570 Cancer Cell 24, November 11, 2013 ª2013 Elsevier Inc.evident between GBM tumors bearing or lacking the K27M mu-
tation (Chan et al., 2013; Lewis et al., 2013; Venneti et al., 2013).
Aberrant levels of histone methylation such as H3K27me3 have
also been reported in other cancers (Dawson and Kouzarides,
2012; Hock, 2012; Kondo et al., 2008; Yoo and Hennighausen,
2012).
K27M mutations may affect transcriptional programs within
the tumors. As EZH2 dysregulation may promote tumorigenesis
depending on the cellular context (Hock, 2012), EZH2-regulated
genes may become aberrantly activated or de-activated in the
presence of mutant H3.3K27M histone, abrogating normal
PRC-mediated repression (Figure 2A). Data strongly suggest
that K27M peptide and H3.3K27M histone allosterically bind
and inhibit the active site of EZH2. Part of the cancer-related
function of free H3.3K27M histones within the nucleus may
be to sequester (Figure 2B) or to trap (Figure 2C) EZH2 at
H3.3K27M chromatin-bound regions. Both scenarios would
prevent PRC2 from binding and spreading K27me3 marks
throughout genomic regions it normally targets, thereby causing
de-repression of these elements (some of which may be onco-
genic). In cultured H3.3K27M DIPG, chromatin immunoprecipi-
tation sequencing (ChIP-seq) measured fewer H3K27me3 peaks
compared to differentiation-matched neural stem cell (NSC)
controls. Interestingly, the relatively lower total abundance of
H3K27me3 peaks was not uniform across genic regions
as some genes exhibited elevated H3K27me3 in DIPG.
Genes in which H3K27me3 was depleted in H3.3K27M DIPG
shared ontology with neurological processes (e.g., OLIG2,
Figures 2B and 2C), while genes in which H3K27me3 was en-
riched possessed ontology of cancer-related pathways (e.g.,
P16INK4A; Chan et al., 2013). The presence of H3.3K27M in-
hibits EZH2 and H3K27me3 on mono and oligo-nucleosomes
(Lewis et al., 2013), suggesting that H3.3K27M itself does
not directly lead to hypermethylated regions. How PRC2methyl-
ates these domains, such as tumor suppressor genes (e.g.,
P16INK4A), in K27M-mutated tumors is still unclear. OLIG2
expression in mutant gliomas was also found to be significantly
higher in K27M samples (Sturm et al., 2012), and several studies
have implicated OLIG2 in gliomagenesis, at least in part through
p53 inactivation (Mehta et al., 2011; Sturm et al., 2012). In this
way, abnormal H3K27me3 levels could be altering specific tran-
scriptional processes within a cell, contributing to oncogenesis.
Oncogenic Mechanisms Linked to H3.3G34R/V
The mechanisms by which H3.3G34R/V mutations contribute
to gliomagenesis are relatively less clear than those proposed
for H3.3K27M. While one study reported an increase in
H3K36me3 levels in a GBM line harboring anH3.3G34Vmutation
(Schwartzentruber et al., 2012), H3K36me3 levels do not appear
to be changed in 293T lines expressing H3.3G34R/V mutants
(Lewis et al., 2013), nor in a H3.3G34V GBM line (Bjerke et al.,
2013). However, introduction of G34R/V mutant histone results
in substantial decreases in K36me3 on the same, and nearby,
nucleosomes (Chan et al., 2013; Lewis et al., 2013). In humans,
SETD2 is the only known methyltransferase that catalyzes
K36me3 of H3/H3.3 (Edmunds et al., 2008), indicating that the
decreases in K36me3 are likely the result of G34R/V mutant his-
tone blocking SETD2 function (Figure 1A). H3K36me2/me3 and
H3K27me3 rarely coexist in chromatin, and H3K36 methylation
Figure 2. The Polycomb Connection
Mutant H3.3K27M can interact with PRC2 to alter transcription in a number of possible scenarios using a representative gene that is dysregulated in K27M
gliomas (OLIG2).
(A) ‘‘Wild type.’’ In this context, H3.3K27M has not been incorporated into the chromatin of OLIG2 (no mutant protein present) and thus does not inhibit PRC2
function. PRC2 is able to trimethylate H3K27, spreading H3K27me3 marks throughout the promoter region and gene body, effectively repressing transcription.
(B) ‘‘Sequestered.’’ H3.3K27M peptide mimics K27 methylation and allosterically inhibits EZH2methyltransferase function outside of chromatin. Free H3.3K27M
in the nucleoplasm may bind to EZH2 through interaction with the active site, sequestering it in the nucleoplasm. Such binding lessens the likelihood of EZH2
binding and silencing its genomic targets.
(C) ‘‘Trapped.’’ In this scenario, H3.3K27M has been incorporated into the promoter/transcriptional start site region. However, binding of EZH2 to H3.3K27M
blocks the active site and interferes with methyltransferase activity of EZH2 on the same and nearby nucleosomes. Thus, this region is not properly silenced and
does not recruit additional silencing factors to spread H3K27me3.
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2011). Likewise, H3.3G34R/V mutations do not appear to affect
the levels of H3K27me3 and H3.3K27Mmutations do not appear
to affect the levels of H3K36me3 (Chan et al., 2013; Lewis et al.,
2013). These data suggest that H3.3K27M and G34R/V-medi-
ated gliomagenesis occur through independent mechanisms.
Methylation of H3/H3.3K36, particularly K36me3, plays some
role in high-grade gliomas because mutations in SETD2 were
found in 15%of exome-sequenced pediatric high-grade gliomas
(Fontebasso et al., 2013b). Along with H3.3G34R/V mutated
tumors, SETD2 mutant high-grade gliomas also localize to the
cerebral hemispheres, although SETD2 mutant tumors fre-
quently contain IDH1 mutations, suggesting that H3.3G34R/V
and SETD2/IDH1 mutations act to disrupt K36me3 in tumors
(Fontebasso et al., 2013b). ChIP-seq analysis of H3K36me3
from a H3.3G34V pediatric GBM cell line identified 156 genes
with differentially enriched H3K36me3 peaks when compared
to a wild-type H3F3A pediatric GBM line, indicating that G34V
may cause distinct changes in K36 methylation at specific re-
gions if not globally (Bjerke et al., 2013). These genes were highly
enriched for ontological processes involving brain development
and cell proliferation. Intriguingly, one of themost highly enriched
genes was MYCN, a known oncogene that can lead to context-
dependent gliomagenesis in Mus (Swartling et al., 2012). Trans-
duction of H3.3G34V into normal human astrocytes andtransformed human fetal glial cells resulted in a 2- to 3-fold in-
crease in MYCN transcript (Bjerke et al., 2013), further support-
ing the hypothesis that H3.3G34V inducesMYCN upregulation in
pediatric gliomas. The potential link between H3.3 and MYCN is
notable given the association of H3.3 with actively transcribed
genes and the role of MYCN in maintaining global euchromatin
in neural stem cells (Knoepfler et al., 2006) and neuroblastoma
(Cotterman et al., 2008).
Nearly all tumors bearing G34R/V mutations in H3F3A also
exhibit mutations in ATRX/DAXX and display alternate length-
ening of telomeres (ALT), a classical phenotype of cancerous
cells (Khuong-Quang et al., 2012; Schwartzentruber et al.,
2012; Sturm et al., 2012). ATRX/DAXX mediates deposition of
H3.3 into pericentromeric and telomeric regions, and chromo-
some ends were found to have demethylated DNA in G34R/V
mutant groups, further implicating a correlation between
G34R/V mutations and ALT. Thus, G34R/V mutations may not
only act to disrupt K36me3 levels and activate potential onco-
genes, but mutations in H3.3 or ATRX/DAXX may potentially
disrupt their proper interaction, leading to aberrant deposition
of H3.3 near telomeric regions and resulting in ALT.
Future Directions and Clinical Implications
A number of open questions remain, including why mutations
specifically in H3F3A are so prominent in cases of pediatricCancer Cell 24, November 11, 2013 ª2013 Elsevier Inc. 571
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deposited in the genome? Equally unclear is what causes the
buildup of H3K27me3 in certain genomic regions of tumors car-
rying H3.3K27M mutations, particularly at tumor suppressor
genes. In addition, do G34R/V mutations act to produce struc-
tural or conformational changes in the N-terminal tail of H3.3,
thereby exerting effects on K36 and other residues that can be
PTM? Although H3.3G34V mutations appear to coincide with in-
creased expression ofMYCN, future studies will need to address
the cellular context of H3K36me3 and H3.3G34V and how com-
mon theMYCN phenotype is in clinically derived tumor samples.
There is a startling degree of overlap between mutations in
H3F3A and ATRX/DAXX (Schwartzentruber et al., 2012). ATRX/
DAXX is responsible for H3.3 deposition in pericentromeric/telo-
meric regions, and loss of ATRX/DAXX is associated with some
degree of genetic instability (Baumann et al., 2010). Because
H3.3 mutant tumors contain CNAs and ALT (Schwartzentruber
et al., 2012; Sturm et al., 2012), it is interesting to speculate
whether altered H3.3 deposition through ATRX/DAXX or H3.3
mutations themselves lead to a loss in genomic integrity. Partial
H3.3 loss-of-function in themouse resulted in genomic instability
(Bush et al., 2013), and H3.3 has been associated with machin-
ery involved in double-strand break repair and homologous
recombination (Jones et al., 2011; Yang et al., 2013) and somatic
hypermutation (Aida et al., 2013).
While some initial work has investigated targeted therapies in a
few H3.3-mutated pediatric tumor types (Bjerke et al., 2013), a
better understanding of these brain tumors will facilitate the
development of novel targeted treatments. The prevalence of
H3.3 mutations in a pediatric setting and the fact that patients
bearing K27M mutations have lower overall survival than
patients bearing G34R/V mutations (Khuong-Quang et al.,
2012; Sturm et al., 2012) highlights the importance of this cancer
pathway. From a broader perspective, it is also possible that the
H3.3 pathway is involved in awider range of cancers throughmu-
tations in chaperones, histone-modifying enzymes, or other mol-
ecules that ultimately feed into the H3.3 functional pathway.
Future studies should address the role of both wild-type and
mutant H3.3 in the genome and epigenome to offer better insight
into howmutation of this intriguing histone variant causes cancer.ACKNOWLEDGMENTS
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